ArticleJapanese journal of radiology2026
Feasibility study of streamlining radioembolization with yttrium-90 resin microspheres without lung shunt fraction measurement for colorectal liver metastasis < 7 cm.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility of streamlining radioembolization using yttrium-90 resin microspheres without lung shunt fraction (LSF) assessment in patients with colorectal liver metastases (mCRC) < 7 cm. MATERIALS AND
methodsThis single-center retrospective study included 32 patients with mCRC who underwent radioembolization between June 2021 and April 2025. Eligibility criteria were: primary target tumor < 7 cm, the sum of the diameters of the two largest tumors ≤ 10 cm, treatment with resin microspheres, omission of LSF measurement, and at least one follow-up imaging study. Radiation activity was prescribed based on tumor location, liver function, and clinical setting, using both single-compartment and multi-compartment dosimetry with assumption of a LSF of 5% and tumor-to-normal (TN) ratio of 3. Post-treatment Y-90 PET/CT dosimetry was performed in 15 patients. Clinical outcomes, tumor response, and treatment-related toxicity were analyzed.
resultsMedian administered radiation activity was 0.50 GBq (IQR, 0.41-0.82). Median mean absorbed dose (mAD) to the perfused tissue was 136 Gy, and median tumor absorbed dose (TAD) was 347 Gy with assumption of TN ratio of 3. Post-treatment PET/CT analysis (n = 15) showed a median TAD of 432 Gy with a median TN ratio of 3.9, and lung dose derived from Y-90 PET/CT image ranged from 0.12 to 0.61 Gy. The best tumor responses were complete response in 12.5%, partial response in 59.4%, and stable disease in 28.1%. One- and two-year local tumor progression-free survival rates were 70.8% and 54.1%, respectively. No patient developed radiation pneumonitis.
conclusionStreamlining radioembolization without LSF assessment appears feasible for patients with mCRC < 7 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.